iTeos Therapeutics to Present Preclinical Data from A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at AACR
A2A Inhibitor TIGIT

iTeos Therapeutics to Present Preclinical Data from A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at AACR

Gosselies, Belgium– April 12, 2018 –iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced that it will present data for its A2Aantagonist and anti-TIGIT antibody programs in two abstracts at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place from April 14-18, 2018 in Chicago, IL.

“We continue to make good progress advancing our best-in-class A2A receptor antagonist and our promising anti-TIGIT antibody toward the clinic and are delighted to present this data at AACR,” said Michel Detheux, Ph.D., Chief Executive Officer of iTeos.“After the advancement of the A2Areceptor antagonist program into the clinic in 2018, the anti-TIGIT antibody will follow in 2019, fortifying our position as a leading player in the immunotherapy field.”

Adenosine A2AReceptor Inhibitor (EOS100850): Best-in-class A2Areceptor antagonistprogram currently being evaluated for safety and efficacy in preclinical models with a Phase I trial expected to begin in 2018.

Presentation Title: EOS100850, an insurmountable and non-brain penetrant A2Areceptor antagonist, inhibits adenosine-mediated T cell suppression, demonstrates anti-tumor activity and exhibits best-in class characteristics

Session Title:Late-Breaking Research: Immunology 2

Session Date and Time:Tuesday, April 17, 2018 from 1:00 PM - 5:00 PM CT
Session Location: Poster Section 44

Human Anti-TIGIT Antibody (EOS884448): Antagonist antibody against human TIGIT that demonstrates a classical human IgG pharmacokinetics profile. It is currently being evaluated for safety and efficacy in preclinical models with a Phase I trial expected to begin in 2019.

Presentation TitleA TIGIT antagonist antibody EOS884448 shows dual mechanism of action by restoration of T cell effector functions and preferential depletion of Treg

Session Title:Late-Breaking Research: Immunology 1

Session Date and Time:Monday, April 16, 2018 from 8:00 AM - 12:00 PM CT
Session Location:Poster Section 45

About iTeos’ Adenosine A2AReceptor Inhibitor (EOS100850)

The adenosine A2Areceptor is the main adenosine receptor expressed on immune cells, which promotes immune suppression, leading to tumor evasion. iTeos’ best-in-class A2Areceptor antagonist, EOS100850, restores T-cell activation inhibited by adenosine. EOS100850 promotes anti-tumor efficacy in mouse tumor models in combination with several immune-checkpoint inhibitors, retains high potency in the presence of elevated intra-tumoral adenosine concentrations, and is non-brain penetrant. EOS100850 is currently being evaluated for safety and efficacy in preclinical models.

About iTeos’ Human Anti-TIGIT Antibody (EOS884448)

Tigit is an immunosuppressive receptor expressed on lymphoid cell populations. TIGIT expression increases in cancer patients and marks exhausted T cells. EOS884448 is an antagonist antibody against human TIGIT. Preclinical studies show its potency to restore T cell function and to preferentially deplete Treg cells in cancer patient material. ADCC/ADCP-enabling isotypes of a-TIGIT surrogate Ab show potent monotherapy efficacy in murine tumor models that correlates to increased T cell activation and reduced Treg infiltration of tumors. EOS884448 demonstrates classical human IgG pharmacokinetics profile and a good developability profile. EOS884448 is currently being evaluated for safety and efficacy in preclinical models.

About iTeos Therapeutics

iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing next generation immunotherapies. The Company is advancing EOS100850, an insurmountable and non-brain penetrant adenosine A2A receptor antagonist, into a Phase I trial in the second half of 2018. A second program for its human ADCC-enabling anti-TIGIT antibody (EOS884448) is expected to enter the clinic in 2019. The company is currently also evaluating its third program, EOS200271, a clinical-stage potent and selective IDO1 inhibitor. Based in Gosselies, Belgium, iTeos Therapeutics was founded out of the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute in 2011, with funds from the LICR, the Walloon Region of Belgium and the European Fund for Economic and Regional Development (FEDER). For more information, please visit www.iteostherapeutics.com.

 

For further information, please contact:

Michel Detheux, CEO

iTeos Therapeutics

info@iteostherapeutics.com

 

Amber Fennell, Mathew Neal, Sukaina Virji, Hendrik Thys

Consilium Strategic Communications

+44 203 709 5700

iteos@consilium-comms.com

 

Sarah McCabe

Stern Investor Relations, Inc.

+ 1 212 362 1200

sarah@sternir.com

Related news

  •  iTeos Therapeutics Awarded €15 Million in Non-Dilutive Funding by the Walloon Region
    A2A Inhibitor Clinical Trials Financial Research TIGIT

    iTeos Therapeutics Awarded €15 Million in Non-Dilutive Funding by the Walloon Region

    Funds will be used to progress iTeos’ two highly innovative clinical-stage oncology programs: a best-in class A2A receptor antagonist and an ADCC-enabled anti-TIGIT antibody drug candidate Gosselies, Belgium and Cambridge, MA – January 30, 2020 – iTeos Therapeutics SA, a privately-held biotechnology company developing innovative cancer immunotherapies, today announced that it has been awarded a total of €15 million in non-dilutive funding to support the clinical development of its two proprietary anti-cancer drug programs, targeting key mechanisms of immunosuppression that are gaining prominence within industry development pipelines. The funding has been approved on behalf of the Walloon Region by Willy Borsus, Minister of Economy and Research. Funding of €11.5 million has been awarded to progress iTeos’ lead candidate EOS-850, a best-in-class adenosine A2A receptor antagonist, and will be used to support the ongoing phase 1b/2a clinical trial, underway at four sites across Europe, and will soon expand to clinical sites in the United States. A second award of €3.5 million will support the Phase 1 clinical trial of iTeos’ fully-human ADCC-enabled anti-TIGIT antibody (EOS-448), which is expected to start in Belgium in February 2020. Michel Detheux, Ph.D., Chief Executive Officer of iTeos, commented, “We are grateful to the Walloon Region for its continued support of iTeos Therapeutics. This investment is invaluable as we seek to progress our two clinical programs. During the last three years, iTeos has developed a comprehensive portfolio of immuno-oncology drug candidates, and these additional Walloon region funds will help us evaluate the performance of our promising lead programs in the clinic.”   For further information, please contact: Michel Detheux, CEO iTeos Therapeutics info@iteostherapeutics.com   Amber Fennell, Catherine Day, Matthew Neal and Sukaina Virji Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com   Sarah McCabe Stern Investor Relations, Inc. +1 212 362 1200 sarah.mccabe@sternir.com

  • iTeos Therapeutics Announces New  Scientific Advisory Board Members
    A2A Inhibitor Clinical Trials Corporate Research TIGIT

    iTeos Therapeutics Announces New Scientific Advisory Board Members

    Gosselies, Belgium and Cambridge, MA – September 9th, 2019 – iTeos Therapeutics SA (iTeos), a privately-held biotechnology company developing novel cancer immunotherapies, today announced that it has added four new world-leading experts in oncology, immunology, and drug discovery and development to its Scientific Advisory Board (SAB): Gordon Freeman,  William Hahn, Ben Stanger and Matt Vander Heiden. The SAB will support the development of iTeos’ pipeline of clinical and preclinical assets targeting key mechanisms of immunosuppression, in order to transform the lives of people living with cancer. The full SAB comprises: Gordon Freeman, Ph.D, Researcher at Boston’s Dana-Farber Cancer Institute, who will become Chairman of the SAB William C. Hahn, M.D.,Ph.D, Chief Research Strategy Officer at Boston’s Dana-Farber Cancer Institute Ben Z. Stanger, M.D, Professor in Cancer Research at the University of Pennsylvania’s Perelman School of Medicine Matthew G. Vander Heiden, Ph.D., Associate Director at the Massachusetts Institute of Technology’s (MIT) Koch Institute for   Integrative Cancer Research Benoit Van den Eynde M.D., Ph.D, Director of the Brussels Branch of the Ludwig Institute for Cancer Research, Ltd. and co-founder of iTeos and previously Chairman of the SAB, will remain a key member of the SAB Pierre Coulie, M.D., Ph.D. Professor of Immunology, the De Duve Institute of the Université Catholique de Louvain Scott Chappel, Ph.D. Chief Scientific Officer at iTeos Therapeutics Michel Detheux, Ph.D., Chief Executive Officer of iTeos, commented: “By assembling this new Scientific Advisory Board, iTeos gains access to a broad range of expertise and extensive knowledge. As we advance our highly-differentiated pipeline of immunotherapies that target the tumor microenvironment, with the aim of enhancing the anti-tumor immune response and addressing some of the limitations of first-generation immunotherapies, their scientific rigour will be invaluable. “While welcoming the new members of the SAB, I would also like to thank the retiring members including Dr. Jean-Yves Bonnefoy, Prof. Vincenzo Bronte, Prof. Vincenzo Cerundolo, Prof. Douglas Fearon, Dr. Jedd Wolchok and Dr. Thomas Gajewski. Their expertise and guidance have been integral to the growth of iTeos Therapeutics and I wish them all well in their future endeavours.” Gordon Freeman, Chairman of the Scientific Advisory Board of iTeos, commented: “I am delighted to be working with, and chairing, the Scientific Advisory Board at iTeos Therapeutics, an exciting company that I have been aware of for a long time and have followed their progress. iTeos’ pipeline of highly selective and potent drug candidates is one that includes some of the most promising drug candidates targeting the A2A pathway as well as TIGIT, a second-generation immune checkpoint inhibitor that is gaining increased interest from big pharma and will enter the clinic in the second half of 2019. I look forward to advising the team through the next stages of their clinical development.” Additional background on all SAB members can be found on the iTeos website. For further information, please contact: Michel Detheux, CEO iTeos Therapeutics info@iteostherapeutics.com   Amber Fennell, Mathew Neal, Sukaina Virji, and Catherine London (US) Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com   Sarah McCabe and Carl Mauch Stern Investor Relations, Inc. + 1 212 362 1200 iTeos@sternir.com

  • iTeos Therapeutics Announces Eight Data Presentations for A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at AACR Annual Meeting 2019
    A2A Inhibitor TIGIT

    iTeos Therapeutics Announces Eight Data Presentations for A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at AACR Annual Meeting 2019

    Gosselies, Belgium and Cambridge, MA – March 29, 2019 – iTeos Therapeutics SA, a privately-held biotechnology company developing novel cancer immunotherapies, today announced that it will present data on the efficacy of its innovative and differentiated A2A receptor antagonist, EOS100850, as well as its human antibody directed against TIGIT, EOS884448, in eight posters at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2019, taking place from March 29 - April 3, 2019 in Atlanta, Georgia.  “We continue to be excited by the preclinical data from our two immuno-oncology programs, both of which promise mono- and combination therapy potential with other anti-cancer treaments,” said Michel Detheux, President and Chief Executive Officer of iTeos Therapeutics. “The preclinical data being presented at AACR demonstrate key differentiation of our A2A receptor antagonist, such as unique prolonged effects of high potency within the adenosine-rich tumor microenvironment and anti-tumor activity in several cancer models and with different drug combinations. The data also provide a deeper understanding of the adenosine pathway in solid tumors. Additionally, our research on the TIGIT activation pathway sheds light on promising strategies to restore anti-tumor immunity.”  The details of the poster presentations are as follows: Title: EOS100850, a non-brain penetrant highly selective A2A receptor antagonist, uniquely maintains high potency within the adenosine rich tumor microenvironment  Session: Novel Immunomodulatory Agents 1 Date & Time: Tuesday, April 2, 2019, 8:00 AM - 12:00 PM ET Authors: Erica Houthuys, et al. Location: Section 25, Poster 3261 Title: EOS100850 potently restores adenosine A2A receptor-dependent suppression of T cell function in the adenosine rich tumor microenvironment  Session: Novel Immunomodulatory Agents 1  Date & Time: Tuesday, April 2, 2019, 8:00 AM - 12:00 PM ET Authors: Erica Houthuys, et al. Location: Section 25, Poster 3278  Title: Extensive characterization of the adenosine pathway in human solid tumors gives a hint on cancer indication selection for the A2A receptor antagonist EOS100850. Session: Novel Immunomodulatory Agents 2 Date & Time: Tuesday, April 2, 2019, 1:00 PM - 5:00 PM ET Authors: Veronique Bodo, et al.  Location: Section 25, Poster 4149  Title: EOS100850 inhibits A2A receptor signaling in human whole blood: two pharmacodynamic assays to monitor EOS100850 activity in clinical studies. Session: Novel Immunomodulatory Agents 2 Date & Time: Tuesday, April 2, 2019, 1:00 PM - 5:00 PM ET Authors: Veronique Bodo, et al. Location: Section 25, Poster 4154 Title: EOS100850, an A2A receptor antagonist with prolonged pharmacodynamic activity, mediates the generation of specific durable immune responses in a murine breast cancer model  Session: Novel Immunomodulatory Agents 2 Date & Time: Tuesday, April 2, 2019, 1:00 PM - 5:00 PM ET Authors: Grégory Driessens, et al.  Location: Section 25, Poster 4147  Title: EOS884448, a high affinity fully human antibody directed against TIGIT, mediates in vitro anti-tumor activity through multiples mechanisms of action involving activation of intratumor effector cells and depletion of regulatory T cells. Session: Immune Checkpoints 1 Date & Time: Tuesday, April 2, 2019, 8:00 AM - 12:00 PM ET Authors: Catherine Hoofd, et al. Location: Section 24, Poster 3240 Title: a-TIGIT mediates antitumor activity through multiple mechanisms of action involving activation of intratumor effector T cells and depletion of regulatory T cells  Session: Immune Checkpoints 1 Date & Time: Tuesday, April 2, 2019, 8:00 AM - 12:00 PM ET  Authors: Grégory Driessens, et al. Location: Section 24, Poster 3249 Title: TIGIT pathway phenotyping sheds light on promising strategies to restore anti-tumor immunity Session: Adaptive Immune Cells in the Tumor Microenvironment Date & Time: Wednesday, April 3, 2019, 8:00 AM - 12:00 PM ET  Authors: Catherine Hoofd, et al. Location: Section 23, Poster 4969 Full poster abstracts are available on the AACR conference website at www.aacr.org.  About iTeos Therapeutics  iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to transforming the lives of persons living with cancer by designing and developing next generation immunotherapies. The Company’s lead program, EOS100850, is an adenosine A2A receptor antagonist currently in a Phase 1/1b study. A second program, a fully human ADCC-enabling anti-TIGIT antibody (EOS884448), is expected to enter the clinic in second half of 2019. Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded through the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain). In 2018, the Company completed a $75 million (€64 million) Series B financing led by MPM Capital, along with new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. Previous investors, including Fund +, VIVES II and SRIW, as well as SFPI, also participated in this funding round. For more information, please visit www.iteostherapeutics.com. For further information, please contact: Michel Detheux, CEO iTeos Therapeutics info@iteostherapeutics.com  Amber Fennell, Mathew Neal, Sukaina Virji Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com Sarah McCabe and Carl Mauch Stern Investor Relations, Inc. + 1 212 362 1200 iTeos@sternir.com